Comparative Pharmacology
Head-to-head clinical analysis: MD 76 versus MD 76R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76 versus MD 76R.
MD-76 vs MD-76R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76 is a contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast between vascular structures and surrounding tissues. It distributes in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
IV: 50-100 mL per dose, administered as a bolus or infusion, not to exceed 3 mL/kg total dose.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Terminal half-life: 1.5–2 hours; prolonged in renal impairment (up to 20 hours in anuria); clinical context: allows rapid elimination, suitable for diagnostic imaging
Terminal half-life 1-2 hours; prolonged in renal impairment.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent